<DOC>
	<DOCNO>NCT02679573</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy delafloxacin compare moxifloxacin treatment adult patient community-acquired pneumonia .</brief_summary>
	<brief_title>Study Compare Delafloxacin Moxifloxacin Treatment Adults With Community-acquired Bacterial Pneumonia</brief_title>
	<detailed_description>The purpose study determine delafloxacin , investigational drug , safe effective treatment community-acquired pneumonia compare moxifloxacin , linezolid case confirm MRSA .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Male female 18 year age old 2 . Evidence acute onset CABP 2 follow symptom ( new worsen ) Cough Production purulent sputum consistent bacterial infection Difficulty breathe Chest pain due pneumonia AND least 2 following finding : Fever ( oral temperature &gt; 38.0°C ) Hypothermia ( oral temperature &lt; 35.0°C ) Tachycardia ( heart rate &gt; 100 beats/min ) Tachypnea ( respiratory rate &gt; 18 breaths/min ) AND least 1 follow finding : Hypoxemia ( oxygen saturation &lt; 90 % PaO2 &lt; 60 mmHg ) room air subject 's baseline [ preCABP study ] supplemental oxygen Clinical evidence pulmonary consolidation and/or presence pulmonary rale An elevated white blood cell count ( WBC ) &gt; 10,000/mm3 15 % immature neutrophil ( band ) , regardless total peripheral WBC count leukopenia WBC &lt; 4500/mm3 3 . Presence lobar , multilobar , patchy parenchymal infiltrate ( ) consistent acute bacterial pneumonia pulmonary imaging study within 48 hour first dose study drug 4 . PORT risk class II V 5 . Must suitable candidate possible IV oral switch antibiotic therapy must also able swallow large tablets/capsules intact without crush 1 . A medical history significant hypersensitivity allergic reaction antibiotic quinolone oxazolidinone class study drug excipients accord investigator 2 . Any infection expect require systemic antibiotic addition study drug 3 . Receipt systemic antibiotic therapy 7 day enrollment one dose single , potentially effective , shortacting antibacterial drug drug regimen CABP within 24 hour enrollment allow limited 25 % enrolled patient At least 48 hour antibiotic therapy CABP clinic note document treatment failure ( i.e. , patient history pulmonary image alone ) new worsen symptom prestudy therapy also allow 4 . Respiratory infection confirm suspected secondary hospitalacquired ventilatorassociated pneumonia require treatment intensive care set , mechanical ventilation 5 . Current suspect diagnosis viral , fungal , aspiration pneumonia , noninfectious cause pulmonary infiltrates , lung cancer , cystic fibrosis , tuberculosis , empyema ( include sterile parapneumonic effusion ) 6 . Known anatomical pathological obstruction history bronchiectasis GOLD Stage 4 COPD history post obstructive pneumonia 7 . Severely compromise immune system 8 . Other exclusion include describe safety label drug quinolone /or oxazolidinone class QT prolongation , proarrhythmic condition , concomitant use drug know cause QT prolongation , peripheral neuropathy , tendon disorder , history myasthenia gravis , liver disease , severe renal disease , seizures concomitant use MAO A B inhibitor agent adrenergic serotonergic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pneumonia</keyword>
</DOC>